

cis-Selective synthesis of 2,5-disubstituted pyrrolidines

Syed Raziullah Hussaini and Mark G. Moloney*

The Department of Chemistry, Dyson Perrins Laboratory, The University of Oxford, South Parks Road, Oxford OX1 3QY, UK


Received 17 October 2003; revised 27 November 2003; accepted 5 December 2003

Abstract—A concise approach to *cis*-2,5-disubstituted pyrrolidines is reported, which relies upon *N*-*tert*-butoxycarbonylmethyl substitution in a substrate derived from pyroglutamic acid. The method is especially noteworthy since a significant improvement in the conditions for a key Lawesson's reaction have been established. Regioselective enolate generation and alkylation permits extension of the C-5 side chain.

© 2003 Elsevier Ltd. All rights reserved.

We recently reported that *trans*-disubstituted pyrrolidines are available by a short sequence from pyroglutamic acid ethyl ester **1a**;¹ thus, conversion to the thiolactam **1b** followed by Eschenmoser sulfur contraction² to give enamine **1c** and catalytic reduction under forcing conditions gave the corresponding 2,5-disubstituted pyrrolidine **2a** as a mixture of diastereomers in excellent yield (Scheme 1). Attempted protection of the

amine functionality with an alkyl substituent proved to be problematic, but after *N*-benzoyl protection, achieved under mild conditions (BzCl, py, 4 h, rt), to give **2b**, regioselective generation of either the C-6 enolate (NaH) or the C-2 enolate (excess LDA), led to adducts **3a** and **4** in good yields exclusively as the *trans*-adducts. Subsequent alkylation of **3a** provided access to 2,5-disubstituted product **3b**; this sequence permits



Scheme 1. Reagents and conditions: (i) Lawesson's reagent, CH₂Cl₂, rt; (ii) BrCH(CO₂Et)₂, NaHCO₃; (iii) H₂ (4.5 atm), PtO₂, TFA, AcOH, 48 h; (iv) PhCOCl, py; (v) NaH, then MeI, THF or PhCH₂Br/DMF; (vi) LDA then PhCH₂Br; (vii) LDA (2 equiv) then MeI; (viii) PhCOCl, Et₃N, DMAP, CH₂Cl₂, 2 days, reflux; (ix) H₂ (5 atm), 10% Pd/C, EtOH, CH₂Cl₂, 24 h.

Keywords: Pyrrolidines; Thionation; Lawesson's reagent.

* Corresponding author. Tel.: +44-1865-275656; fax: +44-1865-275674; e-mail: mark.moloney@chem.ox.ac.uk


regioselective manipulation of the C-2 and/or the C-5 positions independently. The observed *trans*-stereoselectivity was postulated to be due to a ring opening–ring closing equilibration process, assisted by the good leaving group character of the *N*-benzoyl group, leading to the thermodynamically most favourable outcome; a similar equilibration has been reported in closely related substrates.³ We report here that two simple modifications of this procedure significantly improve the efficiency of this process, and cleanly provide access to the corresponding *cis*-2,5-disubstituted series.

The key step of the sequence is activation of the lactam carbonyl of pyroglutamic acid ethyl ester **1a** as the thiocarbonyl derivative **1b**, achieved using either P₂S₅ or Lawesson's reagent; although both methods are known and have been used, the former requires heterogeneous reaction conditions^{4,5} and the latter⁶ seems to be highly solvent dependent. The latter reaction has routinely been conducted in refluxing anhydrous toluene,⁷ but we found that the use of such conditions for the conversion of pyroglutamic acid **1a** to thiopyroglutamic acid **1b** gave modest yields (50%) and, more significantly, a product, which required more than one chromatographic purification in order to obtain material of good enough quality to be used in subsequent steps. The solvents DME⁶ and more recently, anhydrous THF at room temperature, giving a 90% yield of thiolactam **1b**⁸ have been used, although we found that scale-up of this reaction led to a large reduction of yield (21%) and a requirement for multiple chromatographic purifications. Significantly, we have found that the conversion of lactam **1a** to thiopyroglutamic acid **1b** in commercially available HPLC-grade dichloromethane at room temperature for only 1.5 h gives excellent yields of the corresponding product, which was readily purified by a single chromatographic step (0.1 g scale, 78%; 12 g scale, 82%); moreover, the reaction can be conducted on crude ester **1a**.⁹ We believe that the efficiency of this procedure can be attributed to the greater solubility of Lawesson's reagent in DCM compared to other solvents, and the use of room temperature conditions, which avoids the formation of a phosphorus impurity reported previously by Lawesson and co-workers, which is difficult to remove.⁶ These milder conditions are likely to extend the already recognised synthetic applications of Lawesson's reagent.⁷ These preparative difficulties had been addressed earlier by the use of Belleau's reagent¹⁰ but this approach suffers from the fact that the reagent is not commercially available. Thiolactam **1b** could be readily

converted to enamine **1c** in quantitative yield under standard Eschenmoser coupling conditions.

With enamine **1c** reliably in hand, we found that reversal of the order of steps iii and iv of the sequence shown in Scheme 1 leading to the intermediate benzamide **2b** permitted reduction under milder conditions and consequent isolation of the *cis*-isomer. Thus, protection of the enamine function¹¹ of **1c** under forcing conditions (BzCl, Et₃N, DCM, DMAP, 2 days at reflux) gave the *N*-benzoyl derivative **5** in 41% yield, and this was susceptible to reduction under significantly milder conditions than enamine **1c** (10% Pd/C, H₂, 5 atm, 24 h, EtOH/DCM 10:1) to give pyrrolidine **6** as a 9:1 mixture of *cis:trans*-isomers in 79% yield. However, since we had earlier found¹ that alkylation of *cis*-**6** (prepared by a different route) gave only the corresponding *trans*-products after enolate generation, due to the same facile ring opening–ring closing equilibration alluded to above, this compound was of limited synthetic utility for our purpose.

Since the crucial equilibration process leading to the *trans*-product seemed likely to depend on the *N*-benzoyl leaving groups of **2b** and **6**, we expected that this pathway could be effectively blocked by careful choice of the amine protecting group. However, protection of the amine group of compounds like **1c** and **2a** is difficult, due to the hindered nature of the amine function, and attempts at introducing *N*-Me or *N*-Bn groups into **2a** by standard alkylation-type approaches gave recovered starting material, and attempted reductive amination with benzaldehyde gave no identifiable material. Deprotonation of amine **2a** (*cis:trans* = 1:2) with LiHMDS at 0 °C followed by reaction with *tert*-butyl bromoacetate gave the desired adduct **7** in 50% yield, as the *cis*-isomer exclusively (Scheme 2); this isomer is likely to be favoured since an all *trans* arrangement of contiguous substituted ring positions is possible. Significantly, this tertiary amine could be readily purified by chromatography on silica, unlike related compounds, which required distillation.¹² Noteworthy was that the ¹H NMR spectrum of this compound at room temperature gave well resolved signals, unlike the *N*-benzoyl protected series,¹ which required VT analysis at 373 K to give useful spectra, and its stereochemical assignment was based on careful NOE analysis at room temperature (Fig. 1). Simple molecular modeling calculations (ChemDraw with MM2 parameters) suggested that the 2,5-*cis*-isomer was more stable than the corresponding 2,5-*trans*-isomer by 4.8 kJ mol⁻¹, and that the preferred



Scheme 2. Reagents and conditions: (i) LiHMDS (1.5 equiv), 0 °C, THF then BrCH₂CO₂*t*-Bu (50%); (ii) NaH and EtOTf/CH₂Cl₂ or PhCH₂Br/DMF.




Figure 1.

conformation was one in which the C-2 and C-5 substituents were pseudodiaxial and *trans* to the bulky *tert*-butoxycarbonylmethyl substituent. This route is of significance, since the stereoselective synthesis of *cis*-pyrrolidines has been of some recent interest,^{13,14} in particular for their conformational controlling properties,^{15,16} and the application of *N*-methoxycarbonylmethyl derivatives for intramolecular Dieckmann cyclisations leading to pyrrolizidine alkaloids has been reported.³

Compound **7** proved to be amenable to further manipulation, thus reaction with NaH and ethyl triflate in CH₂Cl₂, or benzyl bromide in DMF at room temperature, gave products **8a,b** in 32% (along with 29% of recovered starting material) and 36%, respectively; the regioselectivity of this process was evident from careful NMR spectroscopic analysis and the *cis*-stereochemistry was confirmed by NOE analysis (Fig. 1).¹⁷ For these compounds, molecular modeling calculations (ChemDraw with MM2 parameters) suggested that the 2,5-*cis*-isomers are more stable than the corresponding 2,5-*trans*-isomers by between 2.0 and 4.5 kJ mol⁻¹. We believe that these modest yields are due to the possibility of multiple sites for deprotonation in such a densely functionalised substrate. The importance of heterocyclic *N*-alkylcarbonyl derivatives as conformational controlling elements in biologically relevant ligands has recently been reported.¹⁸

In conclusion, we have shown that efficient modification of the lactam group of pyroglutamic acid and *N*-alkylation of *cis*-2,5-disubstituted pyrrolidines is possible under mild conditions, and that regioselective enolate formation and alkylation permits extension of the appropriate side chain. This neatly complements our earlier work, which permits access to *trans*-2,5-disubstituted pyrrolidines. The application of this methodology for the synthesis of tetrahydroisoquinoline alkaloids is under active investigation in our laboratory.

Acknowledgements

We gratefully acknowledge The University of Oxford (Lady Noon/OUP Fund), St. Peter's College Oxford for a Graduate studentship Award, Lancaster Synthesis for additional support, and the EPSRC Chemical Database Service at Daresbury.¹⁹

References and notes

- Hussaini, S. R.; Moloney, M. G. *Org. Biomol. Chem.* **2003**, *1*, 1838–1841.
- Roth, M.; Dubs, P.; Gotschi, E.; Eschenmoser, A. *Helv. Chim. Acta* **1971**, *54*, 710–734.
- Rabiczko, J.; Urbabczyk-Lipkowska, Z.; Chmielewski, M. *Tetrahedron* **2002**, *58*, 1433–1441.
- Petersen, J. S.; Fels, G.; Rapoport, H. *J. Am. Chem. Soc.* **1984**, *106*, 4539–4547.
- Bachi, M. D.; Breiman, R.; Meshulam, H. *J. Org. Chem.* **1983**, *48*, 1439–1444.
- Andersen, T. P.; Rasmussen, P. B.; Thomsen, I.; Lawesson, S.-O.; Jorgensen, P.; Lindhardt, P. *Liebigs Ann. Chem.* **1986**, 269–279.
- Jesburger, M.; Davis, T. P.; Barner, L. *Synthesis* **2003**, 1929–1958.
- Busque, F.; de March, P.; Figueredo, M.; Font, J.; Gallagher, T.; Milan, S. *Tetrahedron: Asymmetry* **2002**, *13*, 437–445.
- A solution of the lactam and Lawesson's reagent (0.5 equiv) was stirred at room temperature for 1.5 h in dichloromethane, the solvent removed, and the product purified by flash chromatography [EtOAc/petrol (40:60) 2:3].
- Mechelke, M. F.; Meyers, A. I. *Tetrahedron Lett.* **2000**, *41*, 4339–4342.
- For a recent review of the chemistry of enamionones, see: Elassar, A.-Z. A.; El-Khair, A. A. *Tetrahedron* **2003**, *59*, 8463–8480.
- Denmark, S. E.; Matsushashi, H. *J. Org. Chem.* **2002**, *67*, 3479–3486.
- Brun, M.-P.; Martin, A.-S.; Garbay, C.; Bischoff, L. *Tetrahedron Lett.* **2003**, *44*, 7011–7013.
- Mota, A. J.; Langlois, N. *Tetrahedron Lett.* **2003**, *44*, 1141–1143.
- Wallen, E. A. A.; Christiaans, J. A. M.; Saarinen, T. J.; Jarho, E. M.; Forsberg, M. M.; Venalainen, J. I.; Mannisto, P. T.; Gynther, J. *Bioorg. Med. Chem. Lett.* **2003**, *11*, 3611–3619.
- Puschl, A.; Boesen, T.; Zuccarello, G.; Dahl, O.; Pitsch, S.; Nielsen, P. E. *J. Org. Chem.* **2001**, *66*, 707–712.
- The starting material (0.1 g) was dissolved in THF (2 mL) and LiHMDS (1.5 equiv) added at 0 °C. *tert*-Butyl bromoacetate (2 equiv) in THF (3 mL) was added after 15 min at 0 °C. The reaction was allowed to come to rt, stirred for 7 h and quenched at 0 °C using saturated aqueous ammonium chloride, the organic layer washed with water, brine and dried over magnesium sulfate. The product was purified by column chromatography [20% EtOAc, light petroleum (40:60)].
- Minami, N. K.; Reiner, J. E.; Semple, J. E. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 2625–2628.
- Fletcher, D. A.; McMeeking, R. F.; Parkin, D. *J. Chem. Inf. Comput. Sci.* **1996**, *36*, 746–749.